Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Radcliffe Department of Medicine identify a faulty molecular brake that interferes with heart muscle’s ability to contract and relax

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the condition’s cardinal feature—an unusually thick heart muscle that contracts and relaxes abnormally — is fuelled by some glitch in the heart’s molecular machinery. Yet, the precise spark plug that ignites such disordered muscle movement has thus far remained unknown.

Now a new study in Science Translational Medicine has pinpointed a faulty molecular brake that fuels disease development and identified a candidate compound that restores heart muscle function in human and mouse cells.

Read more (Radcliffe Department of Medicine website)

Similar stories

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Two major BHF awards to Neil Herring pave the way to new treatments for heart attack patients

CRE Research

Associate Professor Neil Herring has been awarded a Senior Clinical Research Fellowship and a Project grant from the British Heart Foundation to further critical research into the mechanisms behind heart attacks and heart failure and potential drugs to combat them. Given the 50% reduction in research investment this year from the BHF due to the impact of COVID-19, Prof Herring is to be congratulated on these awards.